jlabs@ NYC QuickFire Challenge
Jlabs @ NYC的居住
挑战
In honor of the Grand Opening of JLABS @ NYC, Johnson & Johnson Innovation has launched a QuickFire Challenge to award up to four new game-changing early-stage innovation companies with the use of a bench, workstation and access to the JLABS @ NYC community for one year.
奖励和利益
Areas of interest
这项比赛将授予在以下领域提交最佳想法，技术或解决方案的人或团队：
- Consumer healthcare
- 健康技术
- 医疗设备
- Therapeutics
常见问题tions
Make sure your browser is up to date and accepting cookies. You can contact customer service athttps://jnjawards.fluidreview.com/helpdesk/contact/如果您也遇到技术困难。
For challenges involving space at JLABS, that entails 1 lab bench and 1 workstation (desk) for 2 people maximum. If you have more employees we can rent out an additional space.
Each applicant will be required to submit to a background check, which is subject to a minimal fee. We also collect a deposit that is refundable at the end of the lease term. There may be other expenses, but this will be dependent on the work that the company is doing in JLABS. There may also be fees associated with EH&S waste, specialty equipment, printing and phone calls.
不，获胜者的任何额外费用和文书工作都取决于获奖者。
Do not submit confidential information. Only non-confidential information should be submitted and anything you submit will be treated as non-confidential.
As this is a no strings attached arrangement, JLABS does not acquire any IP. Any IP creation and/or protection remains the sole responsibility of the inventors.
No, a patent is not required to apply. However, you should not submit any information that you wish to keep confidential or that may negatively impact upon the future patentability of your invention.
我们鼓励所有人申请。了解有关我们希望在这里探索哪些领域的更多信息：https://www.jnjinnovation.com/partnering。
每个挑战都有自己的条款和条件，可以在填写申请书之前找到。
Please contact[电子邮件保护]有任何疑问。
您可以在http:// jnjawards.fluidreview.com。您可以保存工作并登录，以便在需要时在以后的时间完成。
关于Johnson＆Johnson Innovation
Johnson＆Johnson Innovation致力于加快全球创新的所有阶段，并在企业家与Johnson＆Johnson的全球医疗保健业务之间建立合作。Johnson＆Johnson Innovation为科学家，企业家和新兴公司提供一站式访问科学和技术专家，他们可以促进约翰逊和约翰逊的药品，医疗设备和消费者公司的合作。在Johnson＆Johnson Innovation的业务雨伞下，我们通过区域创新中心与创新者（Johnson＆Johnson Innovation）与创新者联系|Jlabs，Johnson＆Johnson Innovation -Jlinx，Johnson＆Johnson Innovation -JJDC和我们的业务开发团队创建定制的交易和小说4个合作，以加快创新发展以解决患者未满足需求的创新。有关更多信息，请访问www.jnjinnovation.com或跟随@JNJInnovation.
关于Johnson＆Johnson Innovation, JLABS
Johnson＆Johnson Innovation，JLABS（JLABS）是一个全球开放创新生态系统的网络，使和授权创新者能够为世界各地的患者创造和加速挽救生命，增强生命的健康和健康解决方案。JLABS通过为新兴公司提供最佳环境来实现这一点明天的突破性医疗解决方案。在JLABS，我们珍视伟大的想法，并热衷于消除成功的障碍，以帮助创新者释放其早期科学发现的潜力。JLABS是一个无弦的模型，这意味着企业家可以在坚持其知识产权的同时自由发展科学。JLABS向包括药品，医疗设备，消费者和数字健康部门在内的广泛医疗保健领域开放企业家。
jlabscurrently has nine locations in innovation hot spots across North America and produces entrepreneurial programs and campaigns to seek out the best science, like the QuickFire Challenges around the globe. The JLABS flagship opened in 2012 in San Diego at Janssen's West Coast Research Center, and since then, has established two locations in San Francisco - one through a collaboration with the California Institute for Quantitative Biosciences (QB3) and a second standalone facility in South San Francisco. JLABS is also located in Boston through a collaboration with LabCentral, in Lowell, Massachusetts through a collaboration with UMass, in Houston through a collaboration with the Texas Medical Center (TMC), in Toronto through a collaboration with the Ontario Government and the University of Toronto and a new JLABS @ NYC (in collaboration with the New York Genome Center -opening in 2018). For more information about JLABS, please visitwww.www.2574design.com。
Winners
LAB11 Therapeutics LLC: Lab11 Therapeutics LLC is a startup biotech company spun out of the Icahn School of Medicine at Mount Sinai. The company is developing host-targeting small molecule broad spectrum anti-viral drugs, with the first indication being anti-influenza A virus (IAV) drugs.
Manhattan Biosolutions：Manhattan Biosolutions是一家生物技术初创企业，旨在发现和开发下一代免疫疗法，以治疗或潜在预防癌症。他们的专有技术平台的目的是增强或增强免疫系统将癌症识别为外来并捍卫身体免受恶性肿瘤的自然能力。
Sapience Therapeutics，Inc。：Sapience Therapeutics是一家临床前生物技术公司，试图开发具有高未满足需求的肿瘤学指示的新型治疗方法。他们的最初目标是开发针对ATF5转录途径的第一类治疗方法，该治疗具有治疗许多癌症的潜力，包括AML，GBM，髓母细胞瘤，神经母细胞瘤，乳腺癌等。
Mobile Sense Technologies, Inc.: Mobile Sense™ is building foundational technology that enables this transformation through off-the-chest wearables for long term management of cardiac arrhythmias. Embedded algorithms coupled with non-adhesive, wireless & waterproof sensors provide high fidelity ECG and PPG recordings.